ArticlePharmacoEconomics2008

Cost-effectiveness analyses of natalizumab (Tysabri) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK.

Ray Gani et al.PubMed ↗Publisher ↗

No numbers read from the abstract.